MicroPort Scientific Announces Capital Injection into MicroPort Vision and Files Prospectus for Its IPO

Gelonghui, March 31 |MicroPort(00853.HK) announced that on March 30, 2021, MicroPort VisionCare, MicroPort Investment (a wholly-owned subsidiary of the Company), and Wangdaotong Biotechnology entered into an agreement with investors regarding capital increase. MicroPort Investment, Wangdaotong Biotechnology, and the second investor each agreed to inject a total of RMB 385 million into MicroPort VisionCare.

MicroPort Vision is currently a subsidiary in which the Group holds a 70% equity interest. The company is primarily engaged in the research and development, manufacturing, and sales of ophthalmic medical products for diagnosis, treatment, and care, as well as the provision of related services. As of the date of this announcement and upon completion of the capital increase, MicroPort Vision is and will continue to be regarded as a subsidiary of the Company. The amount of capital injected was determined with reference to MicroPort Vision’s funding requirements for its activities in researching and developing new technologies and products, as well as for commercial-scale production.